ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announces board changes with the resignation of Mr. Yu Xiaoyong as a non-executive Director, effective September 30, 2024, and the nomination of Ms. Fu Dawei for the same role, pending shareholder approval at an upcoming EGM. Ms. Fu brings over 20 years of experience in investment and technology enterprise management to ImmuneOnco’s board.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.